The demand for blood cancer treatment in USA is projected to grow from USD 2.4 billion in 2025 to USD 5.6 billion by 2035, at a CAGR of 8.6%. Chemotherapy will dominate with a 43.0% market share, while hospitals will lead the end user segment with a 44.0% share.